WO2023152709 - RNA POLYMERASE INHIBITORS AND METHODS USING SAME
National phase entry is expected:
Publication Number
WO/2023/152709
Publication Date
17.08.2023
International Application No.
PCT/IB2023/051227
International Filing Date
11.02.2023
Title **
[English]
RNA POLYMERASE INHIBITORS AND METHODS USING SAME
[French]
INHIBITEURS D'ARN POLYMÉRASE ET PROCÉDÉS LES UTILISANT
Applicants **
ARBUTUS BIOPHARMA CORPORATION
Inventors
COLE, Andrew G.
DUGAN, Benjamin J.
MESAROS, Eugen F.
SOFIA, Michael J.
Priority Data
63/309,965
14.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3985 | |
| EPO | Filing, Examination, Granting | 40008 | |
| Japan | Filing, Examination, Granting | 3446 | |
| South Korea | Filing, Examination, Granting | 4812 | |
| USA | Filing, Examination, Granting | 12390 |
Total:
64,641
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
is selected from the group consisting of (II), (III) and (IV).[French]
est choisi dans le groupe constitué par (II), (III) et (IV).